EUVIMEDEUVIMED entdecken
Crossref

Protective TGFβ2/SMAD3 axis identified by TWAS in papillary thyroid cancer

Qinnan Zhang, Jiayu Tang, Ju Yang, Yujin Li, Xueqing Li, Kangan Wang, Panpan Zhang, Kai Wang, Bingbing Zha iD

Endocrine-Related Cancer · 01.08.2026 · 33 (8)

DOI: 10.1530/erc-25-0405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 15.07.2026. Verfasst von Qinnan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Fifth People's Hospital of Shanghai Fudan University , Shanghai, China. Hauptthemen laut MEDLINE: Smad3 Protein, Transforming Growth Factor beta2, Thyroid Neoplasms, Thyroid Cancer, Papillary. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Although generally indolent, a subset shows aggressive behaviour. Furthermore, the genetic heterogeneity of PTC is not fully explained by known driver mutations, underscoring the need to identify additional susceptibility genes and regulatory mechanisms. To identify additional susceptibility genes and regulatory mechanisms, we integrated transcriptome-wide association studies (TWAS) with summary-data-based Mendelian randomisation (SMR), joint/conditional testing (JCT), and colocalisation analyses across multiple independent cohorts, followed by heterogeneity in dependent instruments (HEIDI) test. Gene prioritisation analyses consistently highlighted TGFB2 and SMAD3 as candidate susceptibility genes for PTC, with SMR supporting putative protective effects. Besides, GEPIA confirmed the positive correlation between TGFB2 and SMAD3 expression in TCGA-THCA. Functional experiments in TPC-1 cells showed that TGFβ2 treatment inhibited cell proliferation and migration, induced apoptosis, and resulted in G0/G1 cell-cycle arrest, accompanied by increased SMAD3 phosphorylation, suggesting activation of canonical TGFβ signalling. Collectively, these findings bridge population-based genetic inference with mechanistic validation and suggest convergent evidence supporting a tumour-suppressive role of the TGFβ2/SMAD3 axis in PTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad3 ProteinTransforming Growth Factor beta2Thyroid NeoplasmsThyroid Cancer, PapillaryHumansGenome-Wide Association StudyApoptosisSignal TransductionCell Proliferation

Stichwörter der Autor:innen

SMAD3TGFB2Mendelian randomisationTWASapoptosiscell cyclepapillary thyroid carcinoma

Substanzen

Smad3 ProteinTransforming Growth Factor beta2SMAD3 protein, humanTGFB2 protein, human

Autor:innen und Institutionen

  • Department of Endocrinology, Fifth People's Hospital of Shanghai Fudan University , Shanghai, China.
  • Department of Thyroid and Breast Surgery, Fifth People's Hospital of Shanghai Fudan University , Shanghai, China.
  • Department of Pathology, Fifth People's Hospital of Shanghai Fudan University , Shanghai, China.

ORCID-Profile: Bingbing Zha

Zitieren

APA

Zhang, Q., Tang, J., Yang, J., Li, Y., Li, X., Wang, K., Zhang, P., Wang, K., & Zha, B. (2026). Protective TGFβ2/SMAD3 axis identified by TWAS in papillary thyroid cancer. Endocrine-Related Cancer, 33(8). https://doi.org/10.1530/erc-25-0405

Vancouver

Zhang Q, Tang J, Yang J, Li Y, Li X, Wang K, et al. Protective TGFβ2/SMAD3 axis identified by TWAS in papillary thyroid cancer. Endocrine-Related Cancer. 2026;33(8). doi:10.1530/erc-25-0405

BibTeX
@article{Zhang2026,
  author = {Zhang, Qinnan and Tang, Jiayu and Yang, Ju and Li, Yujin and Li, Xueqing and Wang, Kangan and Zhang, Panpan and Wang, Kai and Zha, Bingbing},
  title = {Protective TGFβ2/SMAD3 axis identified by TWAS in papillary thyroid cancer},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {8},
  doi = {10.1530/erc-25-0405}
}
Kostenlos starten →